Education
About Us
Working with TipRanks
Follow Us
Getinge AB (GNGBY)
OTHER OTC:GNGBY
Earnings Data
Report Date
Apr 21, 2026Before Open (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
―Last Year’s EPS
0.1Same Quarter Last Year
Based on 0 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The call presents a mixed but constructive picture: underlying operational performance, recurring revenue mix, product launches, regulatory progress and a strong balance sheet are clear positives. However, significant external headwinds — notably tariffs and currency moves — materially suppressed reported margins and profitability in 2025 and are expected to persist into 2026. Additionally, softness in parts of Life Science, supply delays for CardioSave and elevated quality‑related costs temper near‑term visibility. Management is confident in mitigation actions and progression toward the mid‑term margin target, but the combination of solid fundamentals and notable external pressures results in a balanced outlook.Company Guidance
Record quarter with organic revenue growth
Q4 organic net sales grew by 1.2% versus prior year, beating last year's record quarter; order intake increased organically by 2.3%.
Strong underlying margins absent currency/tariff impact
Adjusted EBITA margin excluding currency and tariff effects would have been 20.3% in Q4 and 16.0% for the full year, demonstrating underlying margin improvement toward the 16–19% 2028 target.
Solid profitability and cash generation
Adjusted gross profit in the quarter was SEK 5.037 billion; adjusted EBITDA was SEK 1.809 billion (17.8% margin); free cash flow was SEK 1.2 billion in Q4.
Strong balance sheet and capital allocation actions
Net debt was SEK 9.8 billion (SEK 7.5 billion adjusted for pensions), leverage 1.5x adjusted EBITDA (1.1x adjusted), cash ≈ SEK 3.4 billion; Board proposed dividend SEK 4.75 per share.
Recurring and high‑margin revenue mix improving
Recurring revenue now represents about two‑thirds of sales and the share of high‑margin products (Paragonix, ECLS portfolio, infection‑control consumables, Cell Transfer data bags) has increased.
Product launches and regulatory progress
Several launches in Q4 (Siemens UI in washers/sterilizers, Aquadis 44, Automatiq). Regulatory milestones: CE for PLS set (EUR MDR), iCast covered stent PMA for large diameters, PiCCO included in European guideline; Cardiohelp II CE submission completed and first European shipments expected early in the year.
Commercial momentum in key end markets
Good performance in Acute Care Therapies (ventilators, Transplant Care, ECLS consumables) and Surgical Workflows (operating tables, infection control consumables), and continued strength in sterile transfer within Life Science.
GNGBY Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
GNGBY Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Jan 27, 2026 | $23.76 | $22.59 | -4.94% |
Oct 21, 2025 | $23.05 | $23.64 | +2.57% |
Jul 18, 2025 | $19.39 | $20.78 | +7.14% |
Apr 22, 2025 | $20.05 | $19.01 | -5.17% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Getinge AB (GNGBY) report earnings?
Getinge AB (GNGBY) is schdueled to report earning on Apr 21, 2026, Before Open (Confirmed).
What is Getinge AB (GNGBY) earnings time?
Getinge AB (GNGBY) earnings time is at Apr 21, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is GNGBY EPS forecast?
Currently, no data Available